Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort

Phosphoprotein-based measurements of drug targets and downstream substrates should be captured along with genomic information to identify MBCs driven by the PI3K/AKT/mTOR signalling.